DOI QR코드

DOI QR Code

Engineered Recombinant PON1-OPH Fusion Hybrids: Potentially Effective Catalytic Bioscavengers against Organophosphorus Nerve Agent Analogs

  • Lee, Nari (Department of Microbiologyand Molecular Biology,Chungnam National University) ;
  • Yun, Hyeongseok (Department of Microbiologyand Molecular Biology,Chungnam National University) ;
  • Lee, Chan (Department of Microbiologyand Molecular Biology,Chungnam National University) ;
  • Lee, Yikjae (Department of Microbiologyand Molecular Biology,Chungnam National University) ;
  • Kim, Euna (Department of Microbiologyand Molecular Biology,Chungnam National University) ;
  • Kim, Sumi (Department of Microbiologyand Molecular Biology,Chungnam National University) ;
  • Jeon, Hyoeun (Department of Microbiologyand Molecular Biology,Chungnam National University) ;
  • Yu, Chiho (Agency for Defense Development) ;
  • Rho, Jaerang (Department of Microbiologyand Molecular Biology,Chungnam National University)
  • Received : 2020.06.02
  • Accepted : 2020.07.28
  • Published : 2021.01.28

Abstract

Organophosphorus nerve agents (OPNAs), including both G- and V-type nerve agents such as sarin, soman, tabun and VX, are extremely neurotoxic organophosphorus compounds. Catalytic bioscavengers capable of hydrolyzing OPNAs are under development because of the low protective effects and adverse side effects of chemical antidotes to OPNA poisoning. However, these bioscavengers have certain limitations for practical application, including low catalytic activity and narrow specificity. In this study, we generated a fusion-hybrid form of engineered recombinant human paraoxonase 1 (rePON1) and bacterial organophosphorus hydrolase (OPH), referred to as GV-hybrids, using a flexible linker to develop more promising catalytic bioscavengers against a broad range of OPNAs. These GV-hybrids were able to synergistically hydrolyze both G-type OPNA analogs (paraoxon: 1.7 ~ 193.7-fold, p-nitrophenyl diphenyl phosphate (PNPDPP): 2.3 ~ 33.0-fold and diisopropyl fluorophosphates (DFP): 1.4 ~ 22.8-fold) and V-type OPNA analogs (demeton-S-methyl (DSM): 1.9 ~ 34.6-fold and malathion: 1.1 ~ 4.2-fold above) better than their individual enzyme forms. Among the GV-hybrid clones, the GV7 clone showed remarkable improvements in the catalytic activity toward both G-type OPNA analogs (kcat/Km (106 M-1 min-1): 59.8 ± 0.06 (paraoxon), 5.2 ± 0.02 (PNPDPP) and 47.0 ± 6.0 (DFP)) and V-type OPNA analogs (kcat/Km (M-1 min-1): 504.3 ± 48.5 (DSM) and 1324.0 ± 47.5 (malathion)). In conclusion, we developed GV-hybrid forms of rePON1 and bacterial OPH mutants as effective and suitable catalytic bioscavengers to hydrolyze a broad range of OPNA analogs.

Keywords

References

  1. Chen Y. 2012. Organophosphate-induced brain damage: mechanisms, neuropsychiatric and neurological consequences, and potential therapeutic strategies. Neurotoxicology 33: 391-400. https://doi.org/10.1016/j.neuro.2012.03.011
  2. diTargiani RC, Chandrasekaran L, Belinskaya T, Saxena A. 2010. In search of a catalytic bioscavenger for the prophylaxis of nerve agent toxicity. Chem. Biol. Interact. 187: 349-354. https://doi.org/10.1016/j.cbi.2010.02.021
  3. Nachon F, Brazzolotto X, Trovaslet M, Masson P. 2013. Progress in the development of enzyme-based nerve agent bioscavengers. Chem. Biol. Interact. 206: 536-544. https://doi.org/10.1016/j.cbi.2013.06.012
  4. Masson P, Nachon F. 2017. Cholinesterase reactivators and bioscavengers for pre- and post-exposure treatments of organophosphorus poisoning. J. Neurochem. 142 Suppl 2: 26-40. https://doi.org/10.1111/jnc.14026
  5. Lockridge O, Blong RM, Masson P, Froment MT, Millard CB, Broomfield CA. 1997. A single amino acid substitution, Gly117His, confers phosphotriesterase (organophosphorus acid anhydride hydrolase) activity on human butyrylcholinesterase. Biochemistry 36: 786-795. https://doi.org/10.1021/bi961412g
  6. Millard CB, Lockridge O, Broomfield CA. 1998. Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: synergy results in a somanase. Biochemistry 37: 237-247. https://doi.org/10.1021/bi972057c
  7. Josse D, Lockridge O, Xie W, Bartels CF, Schopfer LM, Masson P. 2001. The active site of human paraoxonase (PON1). J. Appl. Toxicol. 21 Suppl 1: S7-11. https://doi.org/10.1002/jat.789
  8. Valiyaveettil M, Alamneh Y, Rezk P, Biggemann L, Perkins MW, Sciuto AM, et al. 2011. Protective efficacy of catalytic bioscavenger, paraoxonase 1 against sarin and soman exposure in guinea pigs. Biochem. Pharmacol. 81: 800-809. https://doi.org/10.1016/j.bcp.2010.12.024
  9. Brushia RJ, Forte TM, Oda MN, La Du BN, Bielicki JK. 2001. Baculovirus-mediated expression and purification of human serum paraoxonase 1A. J. Lipid Res. 42: 951-958. https://doi.org/10.1016/S0022-2275(20)31619-9
  10. Aharoni A, Tawfik DS. 2004. Directed evolution of recombinant serum paraoxonase (PON) variants. Discov. Med. 4: 120-124.
  11. Kirby SD, Norris JR, Richard Smith J, Bahnson BJ, Cerasoli DM. 2013. Human paraoxonase double mutants hydrolyze V and G class organophosphorus nerve agents. Chem. Biol. Interact. 203: 181-185. https://doi.org/10.1016/j.cbi.2012.10.023
  12. Goldsmith M, Ashani Y, Simo Y, Ben-David M, Leader H, Silman I, et al. 2012. Evolved stereoselective hydrolases for broad-spectrum G-type nerve agent detoxification. Chem. Biol. 19: 456-466. https://doi.org/10.1016/j.chembiol.2012.01.017
  13. Gupta RD, Goldsmith M, Ashani Y, Simo Y, Mullokandov G, Bar H, et al. 2011. Directed evolution of hydrolases for prevention of G-type nerve agent intoxication. Nat. Chem. Biol. 7: 120-125. https://doi.org/10.1038/nchembio.510
  14. Worek F, Seeger T, Goldsmith M, Ashani Y, Leader H, Sussman JS, et al. 2014. Efficacy of the rePON1 mutant IIG1 to prevent cyclosarin toxicity in vivo and to detoxify structurally different nerve agents in vitro. Arch. Toxicol. 88: 1257-1266. https://doi.org/10.1007/s00204-014-1204-z
  15. Masson P, Rochu D. 2009. Catalytic bioscavengers against toxic esters, an alternative approach for prophylaxis and treatments of poisonings. Acta Naturae 1: 68-79. https://doi.org/10.32607/20758251-2009-1-1-68-79
  16. Jeong YS, Choi JM, Kyeong HH, Choi JY, Kim EJ, Kim HS. 2014. Rational design of organophosphorus hydrolase with high catalytic efficiency for detoxifying a V-type nerve agent. Biochem. Biophys. Res. Commun. 449: 263-267. https://doi.org/10.1016/j.bbrc.2014.04.155
  17. Bigley AN, Mabanglo MF, Harvey SP, Raushel FM. 2015. Variants of phosphotriesterase for the enhanced detoxification of the chemical warfare agent VR. Biochemistry 54: 5502-5512. https://doi.org/10.1021/acs.biochem.5b00629
  18. Bigley AN, Xu C, Henderson TJ, Harvey SP, Raushel FM. 2013. Enzymatic neutralization of the chemical warfare agent VX: evolution of phosphotriesterase for phosphorothiolate hydrolysis. J. Am. Chem. Soc. 135: 10426-10432. https://doi.org/10.1021/ja402832z
  19. Lushchekina S, Masson P. 2018. Catalytic bioscavengers against organophosphorus agents: mechanistic issues of self-reactivating cholinesterases. Toxicology 409: 91-102. https://doi.org/10.1016/j.tox.2018.07.020
  20. Tafesse F. 1998. Hydrolysis of nerve agent simulants by synergistic effects of tetraminecobalt(III) and microemulsions. Inorg. Chim. Acta 269: 287-291. https://doi.org/10.1016/S0020-1693(97)05793-9
  21. Yun H, Yu J, Kim S, Lee N, Lee J, Lee S, et al. 2017. Expression and purification of biologically active recombinant human paraoxonase 1 from a Drosophila S2 stable cell line. Protein Expr. Purif. 131: 34-41. https://doi.org/10.1016/j.pep.2016.11.003
  22. Yun H, Lee S, Kim S, Yu J, Lee N, Lee J, et al. 2017. Improved hydrolysis of organophosphorus compounds by engineered human prolidases. Protein Pept. Lett. 24: 617-625.
  23. Vartanian JP, Henry M, Wain-Hobson S. 1996. Hypermutagenic PCR involving all four transitions and a sizeable proportion of transversions. Nucleic Acids Res. 24: 2627-2631. https://doi.org/10.1093/nar/24.14.2627
  24. Otto TC, Harsch CK, Yeung DT, Magliery TJ, Cerasoli DM, Lenz DE. 2009. Dramatic differences in organophosphorus hydrolase activity between human and chimeric recombinant mammalian paraoxonase-1 enzymes. Biochemistry 48: 10416-10422. https://doi.org/10.1021/bi901161b
  25. Aubert SD, Li Y, Raushel FM. 2004. Mechanism for the hydrolysis of organophosphates by the bacterial phosphotriesterase. Biochemistry 43: 5707-5715. https://doi.org/10.1021/bi0497805
  26. Goldsmith M, Aggarwal N, Ashani Y, Jubran H, Greisen PJ, Ovchinnikov S, et al. 2017. Overcoming an optimization plateau in the directed evolution of highly efficient nerve agent bioscavengers. Protein Eng. Des. Sel. 30: 333-345. https://doi.org/10.1093/protein/gzx003
  27. Cherny I, Greisen P, Jr., Ashani Y, Khare SD, Oberdorfer G, Leader H, et al. 2013. Engineering V-type nerve agents detoxifying enzymes using computationally focused libraries. ACS Chem. Biol. 8: 2394-2403. https://doi.org/10.1021/cb4004892